Acquired Resistance to Therapy Network (ARTNet)
ARTNet (funded through RFA-CA-21-052/RFA-CA-21-053 by DCB and the NCI Division of Cancer Treatment and Diagnosis) focuses on the mechanistic bases of acquired resistance to cancer therapies and disease recurrence.
Its central goal is to balance basic, pre-clinical, and translational research using an iterative team science structure that will enable hypothesis testing on the biological basis of resistance in clinically relevant model systems.
ARTNet also aims to provide evidence along the shared tumor-tumor microenvironment (TME) continuum to inform new strategies that can be better translated into future clinical trials.
Collectively, the network represents a range of treatment modalities (e.g., chemotherapy, radiation, targeted agents, immunotherapies, combined modalities) and cancer types in pursuit of addressing compelling questions and significant barriers in acquired therapy resistance research.
ARTNet News
Recent ARTNet updates, including information about the ARTNet Bi-Annual Meeting, investigator news, recent publications, working groups, shared resources, and more can be found in the ARTNet Newsletter.
ARTNet Digital Media
Learn more about ARTNet via the following digital media platforms:
- ARTNet Website
- ARTNet Twitter: @NCIARTNet
DCB Contact for ARTNet
For additional information about ARTNet, please contact Dr. Jeff Hildesheim.
Funded Projects
ARTNet Research Centers (U54s)
Institution | Principal Investigator(s) | Center Title |
---|---|---|
MD Anderson Cancer Center | Boyi Gan, Albert Koong | Acquired Resistance to Therapy and Iron (ARTI) Center |
MD Anderson Cancer Center | Jefferey N. Myers, Vlad C. Sandulache | The Houston Center for Acquired Resistance Research (H-CARR) |
Oregon Health and Science University | Jeffery W. Tyner, Brian J. Druker, Shannon K. McSweeney | Architecture and Trajectory of Acquired Resistance to Therapy in AML |
University of California, San Francisco | Trever G. Bivona, Jack Roth | Bay Area & Anderson Team Against Acquired Resistance - U54 Program (BAATAAR-UP) |
University of Oklahoma Health Sciences Center | Pankaj K. Singh |
ARTNet Coordinating and Data Management Center (U24)
Institution | Principal Investigator(s) | Center Title |
---|---|---|
Roswell Park Cancer Institute | Alan D. Hutson, David W. Goodrich, Song Liu, Martin T. Morgan | Coordinating and Data Management Center for Acquired Resistance to Therapy Network |